3556 Infliximab Infliximab is a tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. 170277-31-3 36105.69499999999 Clear solution. 61°C (FAB fragment), 71°C (whole mAb) >10 mg/mL Intravenous injection. Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa. Neutralization of the biological activity of TNFa leads to an overall reduction in inflammation. Free toxin may be removed by opsonization via the reticuloendothelial system (primarily the liver and kidneys) or it may be degraded through cellular internalization via the lysosomes. Lysosomes are membrane-enclosed organelles that contain an array of digestive enzymes, including several proteases. Half Life: 9.5 days Not listed by IARC. To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis. 2009-07-30T17:58:58Z 2014-12-24T20:26:07Z Infliximab P01857 DB00065 1AJ7 true Exogenous Liquid CHEMBL1201581 4g3y_bio_r_500.jpg image/jpeg 51312 2014-10-14T18:14:18Z BSEQ0005514